What's Happening With Regeneron Pharmaceuticals Stock On Monday?
1. REGN shared Phase 3 trial results for cat and birch allergy treatments. 2. Both trials met primary and key secondary endpoints, showing significant symptom reduction. 3. No serious adverse events were reported, indicating favorable safety profiles. 4. Downward market pressure noted as REGN stock declined by 3.05%. 5. Future developments planned for allergy treatments in 2026 and end of 2023.